For information about COVID-19, including symptoms and prevention, please read our COVID-19 patient guide. If you need to see your provider, please contact us to see if a Video Visit is right for you. Please also consider supporting Weill Cornell Medicine’s efforts against the pandemic.
Department of Medicine

You are here

Targeting the Type 1 Interferon Pathway to Treat Lupus: Dr. Crow Provides Perspective in Science

Dr. Mary Crow

In a perspective published in Science, Dr. Mary K. Crow, Chief, Division of Rheumatology, WDOM, and the Physician-in-Chief and Chair of Medicine at Hospital for Special Surgery, has provided an analysis on new research findings involving the overproduction of type 1 interferon in lupus. The new research has yielded data on one of the mechanisms that might explain why interferon is being made in excess in lupus, and Dr. Crow notes this advance “also supports therapeutic targeting of the interferon pathway in lupus.”

Related Links

Perspective in Science
HSS Newsroom